Tag: Corvia

Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients

44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today…

REDUCE LAP-HF II ANALYSES SHOW 50% OF STUDY PATIENTS DEMONSTRATED SIGNIFICANT CLINICAL BENEFIT FROM THE CORVIA® ATRIAL SHUNT

Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, […]

Corvia Medical Completes Randomization In REDUCE LAP-HF II Pivotal Trial And Gains FDA Authorization To Provide Continued Access For The Corvia Atrial Shunt

Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, Mass., Nov. 17, 2020 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization […]

Corvia Medical’s Interatrial Shunt Device (IASD®) Receives Breakthrough Device Designation For Heart Failure

TEWKSBURY, Mass., Oct. 9, 2019 /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its […]

Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Clinical Trial to Leverage Novel Digital Endpoints

BOSTON–(BUSINESS WIRE)–Corvia Medical has sponsored and is actively enrolling patients in an innovative heart failure (HF) device trial that, in addition to measuring traditional heart failure endpoints, includes collecting and analyzing biosensor data with physIQ’s continuous remote monitoring platform. The […]

Corvia Medical Announces Strong Positive One-Year Data From REDUCE LAP-HF I Randomized, Sham-Controlled Clinical Trial

MUNICH, Aug. 27, 2018 /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced one-year follow-up data from the REDUCE LAP-HF I clinical study of its Interatrial Shunt Device (IASD®). The IASD is […]

Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD System II for the Treatment of Heart Failure

ANAHEIM, Calif., Nov. 14, 2017 /PRNewswire/ — Corvia Medical, Inc., a privately-held medical device company that developed a first-in-class transcatheter structural heart device to treat heart failure, today announced that it has enrolled the first patients in its global multicenter […]